Rt Hon JACINDA ARDERN (Prime Minister): Yes, particularly the recent announcement that Pharmac has signed an agreement for 60,000 courses of Pfizer's oral antiviral treatment. Clinical studies have shown this treatment is highly promising, with an 89 percent reduction in hospitalisations and deaths. Taken orally at the first sign of symptoms, it can significantly prevent people from getting really unwell and requiring hospitalisation. The Government's decision to ring-fence $300 million for Pharmac to purchase COVID-19 therapeutics, on top of an existing $175 million for medicines and supply chain costs, means New Zealanders will have access to six world-leading therapeutics. Three of these are already in use in our hospitals, and we're seeing the impact of that. Pending Medsafe approval, the remainder is scheduled to arrive in New Zealand early next year.